Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

President of R&D

General Counsel

Chief Executive Officer

Chief Regulatory Officer

Vice President, Finance

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and o...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	Chief Financial Officer
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	-
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	President of R&D
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	General Counsel
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	-
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2024-03-22	Premium	back to issuer	Premium	Premium	Premium	Chief Regulatory Officer
2024-03-13	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-03-13	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-02-12	Premium	acquired	Premium	Premium	Premium	-
2024-02-12	Premium	sold	Premium	Premium	Premium	-
2024-01-24	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-24	Premium	acquired	Premium	Premium	Premium	President of R&D
2024-01-24	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-24	Premium	acquired	Premium	Premium	Premium	Chief Regulatory Officer
2024-01-24	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-19	Premium	sold	Premium	Premium	Premium	President of R&D
2024-01-19	Premium	acquired	Premium	Premium	Premium	President of R&D
2024-01-16	Premium	sold	Premium	Premium	Premium	General Counsel
2024-01-16	Premium	acquired	Premium	Premium	Premium	General Counsel
2024-01-16	Premium	sold	Premium	Premium	Premium	Vice President, Finance
2024-01-16	Premium	acquired	Premium	Premium	Premium	Vice President, Finance
2024-01-10	Premium	sold	Premium	Premium	Premium	-
2024-01-10	Premium	acquired	Premium	Premium	Premium	-
2023-12-18	Premium	sold	Premium	Premium	Premium	President of R&D

CBAY - Cymabay Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CBAY